Follow-up study for people previously treated with NTLA-2001
Part of Brain & nervous system, Genetic & congenital, Hormones & metabolism clinical trials.
This study checks how people are doing long-term after receiving NTLA-2001 in an Intellia clinical trial. If you previously took part and agree to be followed, this may help the researchers understand lasting safety and effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You previously finished or stopped a past Intellia study where you received NTLA-2001.
- Your earlier study may have been a full or partial dose.
- You must be willing to sign (or already signed) informed consent for this follow-up.
- No other specific health conditions are listed as reasons to not join.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at people who carry certain TTR gene variants, which can cause a specific type of heart amyloid buildup. It also includes people with symptoms, to understand how the condition develops and how it may be monitored.
This study follows people who previously got the experimental drug NTLA-2002 in an Intellia trial. It checks long-term safety and health effects, even if you already stopped treatment.
This study tests a new treatment, NTLA-2001, for people with a type of heart disease called transthyretin amyloidosis with cardiomyopathy. It aims to see if the medicine can help improve heart function and quality of life.
This study is testing a new gene-silencing treatment called NTLA-2001 for people with hereditary ATTR amyloidosis that causes nerve damage. It works by stopping the body from making a faulty protein that builds up and harms nerves.
This study is an extension of a previous trial (study 301) for adults with a heart condition called transthyretin amyloid cardiomyopathy. It aims to evaluate the long-term safety and effectiveness of an investigational drug (ALXN2220). Participants who completed the earlier study without stopping the drug or withdrawing consent may be eligible to continue receiving the treatment.
This trial follows up with people who already received a Century Therapeutics cellular therapy treatment. It mainly checks how you’re doing over time and whether the treatment has lasting effects.
Hear when a new Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.